Related Experiment Videos
Antihypertensive drug therapy in older patients
1Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium.
Insights
Drug treatment effectively lowers high systolic blood pressure in elderly patients. Benefits are most significant for older men and those with existing cardiovascular issues or higher pulse pressure.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Pharmacology
Background:
- Elevated pulse pressure is a significant cardiovascular risk factor in the elderly population.
- The reversibility of elevated pulse pressure in older adults requires further investigation.
- Isolated systolic hypertension in the elderly (systolic blood pressure ≥ 160 mmHg) may warrant drug treatment.
Purpose of the Study:
- To evaluate the efficacy and benefits of drug treatment for isolated systolic hypertension in the elderly.
- To identify patient subgroups who experience the greatest absolute benefit from antihypertensive therapy.
Main Methods:
- Analysis of data from comparative trials focusing on blood pressure gradients and outcomes.
- Assessment of cardiovascular protection offered by different drug classes, including calcium-channel blockers.
- Examination of potential outcome benefits of angiotensin-converting enzyme inhibitors and alpha-blockers beyond blood pressure reduction.
Main Results:
- Drug treatment is indicated for elderly patients with isolated systolic hypertension (systolic blood pressure ≥ 160 mmHg).
- Absolute benefits of treatment are more pronounced in men, individuals aged 70 years and older, and those with prior cardiovascular complications or greater pulse pressure.
- Calcium-channel blockers demonstrate comparable overall cardiovascular benefits to older drug classes, potentially offering greater stroke protection than myocardial infarction protection.
Conclusions:
- Drug treatment is justified and beneficial for managing isolated systolic hypertension in the elderly, particularly in specific subgroups.
- Blood pressure reduction is the primary driver of improved outcomes in antihypertensive therapy.
- Further research is needed to confirm if angiotensin-converting enzyme inhibitors or alpha-blockers provide benefits beyond their blood pressure-lowering effects.
Abstract:
Elevated pulse pressure is an important cardiovascular risk factor in the elderly, and it remains to be determined whether this can be reversed. Drug treatment is justified in older patients with isolated systolic hypertension whose systolic blood pressure is 160 mmHg or higher on repeated measurement. Absolute benefit is greater in men, in patients aged 70 years or more, and in those with previous cardiovascular complications or greater pulse pressure. In the recently published comparative trials blood pressure gradients largely accounted for most, if not all, of the differences in outcome. In hypertensive patients, calcium-channel blockers may offer greater protection against stroke than against myocardial infarction, resulting in an overall cardiovascular benefit similar to that provided by older drug classes. The hypothesis that angiotensin-converting enzyme inhibitors or alpha-blockers might influence outcome over and beyond that expected on the basis of their blood pressure lowering effects still remains to be proved.